Tailored Therapies for IBD: A Look into the Future

October 5–6, 2018
Milan Marriott Hotel
Milan, Italy

Program
10 credit hours (CME) have been awarded for the Symposium 213 by the European Union of Medical Specialists (UEMS).
Preface

The mechanisms underlying the chronic intestinal inflammation that is a hallmark of inflammatory bowel diseases (IBD) are complex. Advances in the understanding of IBD pathogenesis have resulted in the development of multiple biological agents that all represent an alternative to the use of current therapies in patients with refractory Crohn’s disease or ulcerative colitis.

However biomarkers and patient stratification is key to personalize treatment in IBD. As clinicians we may oversimplify the complex nature of IBD and pay not enough attention to the heterogeneity of the pathophysiology and clinical presentation of these disorders. Taking into account specific risk factors, genetic phenotypes, pharmacokinetic characteristics, and other particular features unique to each patient would allow a personalized approach to manage the disease. Personalized medicine therefore represents the tailoring of the medical approach and treatment to the individual characteristics of each patient and is expected to become the paradigm of future healthcare.

The advancements in systems biology research and the rapid development of high-throughput technologies, as well as the characterization of different -omics, will contribute to a shift in modern biological and medical research from traditional hypothesis-driven designs toward data-driven studies and will facilitate the evolution of personalized or precision medicine for chronic diseases such as Crohn’s disease and ulcerative colitis.

The aim of this Falk Symposium is to dive into possibilities of personalized medicine for IBD patients. All speakers and moderators are internationally recognized IBD experts and build the basis for an up-to-date state-of-the-art symposium on IBD. The program is designed to provide opportunities for ample discussion and interaction with speakers, moderators and attendees.

We like to welcome you in Milan, the capital of tailors and designers, which will provide a perfect setup for a meeting on tailored therapies.

S. Danese  A. Armuzzi  A. Dignass  P. Gionchetti
Tailored Therapies for IBD: A Look into the Future

October 5–6, 2018
Milan Marriott Hotel
Milan, Italy

Start of Registration:
Thursday, October 4, 2018
16.00 – 21.00 h
at the congress office

Setting Up of Poster Session:
Thursday, October 4, 2018
16.00 – 21.00 h

Congress Venue:
Milan Marriott Hotel
Via Washington 66
20146 Milan
Italy

Symposium 213 is organized by Falk Foundation e.V.

Scientific Organization:
Prof. Dr. Silvio Danese
IRCCS in Gastroenterology
Istituto Clinico Humanitas IRCCS
Via Manzoni 56
20089 Rozzano
Italy
Telephone: +39-0282-2482-82
Telefax: +39-0282-2451-01
E-mail: s.danese@hotmail.com

Scientific Co-Organization:
A. Armuzzi, Rome (Italy)
A. Dignass, Frankfurt (Germany)
P. Gionchetti, Bologna (Italy)

Official Language:
English
Friday, October 5, 2018

9.00 Welcome
S. Danese, Milan

Session I
Predicting good or bad prognosis
Chair: G. Fiorino, Milan; A. Sturm, Berlin

9.10 Genetic and clinical features for natural history
V. Annese, Dubai

9.30 Endoscopy to tailor choices
M. Daperno, Turin

9.50 Radiology to predict natural history
G. Fiorino, Milan

10.10 Biomarkers and prognosis
M.C. Dubinsky, New York

10.30 Coffee break with poster session

Session II
Conventional therapies:
Optimizing therapies to patient profiles
Chair: J. Lindsay, London; B. Siegmund, Berlin

11.00 Steroids: Old and new formulations
S.P.L. Travis, Oxford

11.20 5-ASA in UC: Outdated or still state-of-the-art?
A. Dignass, Frankfurt

11.40 Azathioprine: Outdated or still a valid option for UC and CD?
F. Baert, Roeselare

12.00 Methotrexate in CD and UC after METEOR
F. Carbonnel, Paris

12.20 Lunch break with poster session
Friday, October 5, 2018

Session III
Anti-TNF: A tailor made approach

Chair: M. Allez, Paris; F. Rizzello, Bologna

14.20 Predicting response: The best patient  
Y. Chowers, Haifa

14.40 Predicting loss of response  
I. Dotan, Petah Tikva

15.00 Optimizing anti-TNF therapy  
M. Ferrante, Leuven

15.20 Tailoring interruption of anti-TNF in IBD  
E. Louis, Liège

15.40 Coffee break with poster session

Session IV
Vedolizumab and ustekinumab

Chair: R. Atreya, Erlangen; S. Schreiber, Kiel

16.10 Vedolizumab in UC: For all patients or best patient profile  
B.E. Sands, New York

16.30 Vedolizumab in CD: For all patients or best patient profile  
S. Schreiber, Kiel

16.50 Ustekinumab: Who and when?  
W.J. Sandborn, La Jolla

17.10 Safety of biologics in IBD: Recent updates  
S. Bonovas, Milan

17.30 State-of-the-Art Lecture: Predicting the future of treatment for IBD  
C. Fiocchi, Cleveland

18.00 Scientific discussion with snacks
Saturday, October 6, 2018

Session V
New molecules

Chair: F.J. Magro, Porto; G. Rogler, Zurich

9.00 JAKs
R. Panaccione, Calgary

9.20 New anti-adhesion molecules
S. Ghosh, Birmingham

9.40 Sphingosine-1-phosphate receptor modulators in the treatment of IBD
B.G. Feagan, London, CA

10.00 Anti-fibrotic drugs for Crohn’s?
G. Rogler, Zurich

10.20 New anti-IL23 blockers
M.C. Fantini, Rome

10.40 Coffee break with poster session

Session VI
Tailoring surgery to patients

Chair: W.A. Bemelman, Amsterdam; Y. Panis, Clichy

11.10 Tailoring surgery in UC: Always proctocolectomy
A. D’Hoore, Leuven

11.30 Tailoring surgery in CD
A. Spinelli, Milan

11.50 Perianal Crohn’s disease
S. Steele, Cleveland

12.10 Perioperative medications
M. Vecchi, Milan

12.30 Presentation of Poster Awards
S. Danese, Milan
A. Dignass, Frankfurt

12.50 Lunch break with poster session
Saturday, October 6, 2018
Session VII
Challenging clinical scenarios

Chair: A. Armuzzi, Rome; B.E. Sands, New York

14.00 Patient with previous cancer  L. Beaugerie, Paris
14.20 A patient with previous opportunistic infections  J. Lindsay, London
14.40 Crohn’s disease and tuberculosis in endemic areas  F. Gomollón, Zaragoza

15.10 Fistulising CD:
- Pro medical treatment  P. Gionchetti, Bologna
- Pro surgical treatment  P.G. Kotze, Curitiba

15.40 Closing remarks  P. Gionchetti, Bologna
                          A. Armuzzi, Rome
1.* Crohn's and ulcerative colitis questionnaire-8 (CUCQ-8), a valid and quick quality of life measure in IBD  
L. Alrubaiy, P. Dodds, H. Hutchings, J.G. Williams (Swansea, GB)

2.* Inflammatory bowel disease in the UK: Is care improving?  

3. Clinicians' knowledge about the ionizing radiation of the common investigations used in inflammatory bowel disease  
L. Alrubaiy, A. Rikaby, S. Al-Rubaye, C.L. Ch’ng (Swansea, London, GB)

4. Conservative treatment of patients after excision of chronic anal fissure  
P. Andreev, O. Davydova (Samara, RU)

5. Cognitive behavioural therapy for the management of inflammatory bowel disease-fatigue: A pilot randomised controlled trial  


7. Disease phenotype and features for natural history of paediatric-onset ulcerative colitis  
M. Baycheva, R. Shentova, P. Hadjiiski, D. Kofinova, P. Yaneva (Sofia, BG)

8.* Anti-tumour necrosis factor drug cessation in IBD – A source of anxiety?  
F. Betteridge, L. Materacki, K. Yong, D. Murugiah, S. Mullens, V. Cambridge, B. Colleypriest, J. Saunders (Bath, GB)

9. Comparison of long-standing pediatric-onset and adult-onset inflammatory bowel disease  

10. An association between anti-Saccharomyces cerevisiae antibodies (ASCA) and recurrent ileitis following total colectomy: A case series  

11. Recurrent Sweet's syndrome secondary to ulcerative colitis: An uncommon association  

12. Leucopenia in a patient with Crohn's and Von Gierke's (glycogenosis 1b) disease  
N. Blazevic, M. Nikolic, A. Muslim, M. Zivkovic, I. Budimir, A. Biscanin, D. Hrabar, Z. Dorosulic (Zagreb, HR)

13. Surgical rates for Crohn's disease: A monocentric cross section study from Turkey  
14. Possible complications during treatment of patients with M. Crohn – Case report V. Bulat, B. Veljkovic (Belgrade, CS)
15. Clinical outcomes after elective discontinuation of anti-TNF therapy in patients with Crohn's disease V. Cambridge, J. Saunders (Bath, GB)
16. Changing patterns of frequency of ulcerative colitis in Lima, Peru H. Cedron (Lima, PE)
20. Clinical relevance of probiotic on long-term maintenance therapy outcomes I. Copaci, G. Constantinescu, L. Micu, A. Franculescu-Bertea (Bucharest, RO)
21. Developing a faecal transplantation donor bank for the treatment of ulcerative colitis A. Cunningham, R. Kokelaar, M. Jitsumura, D. Harris (Swansea, GB)
22. Corticosteroid therapy in patient with synchronous Crohn's ileitis and non-Hodgkin lymphoma type DLBCL I. Curlin, I. Romic (Dubrovnik, HR)
25.* Intestinal microbiota changes in urban and rural patients with inflammatory bowel diseases N. Danilova, M. Markelova, S. Abdulkhakov, T. Grigoryeva, A. Tyakht, A. Pavlenko, A. Odintsova, R. Abdulkhakov (Kazan, Moscow, RU)
26. The role of microbiological research in the treatment of patients with severe attack of ulcerative colitis O. Davydova, P. Andreev (Samara, RU)
28. The prevalence of viral markers at patients with inflammatory bowel diseases
C.I. Deliu, O.M. Diaconu, N. Deliu, D. Neagoe, A.-V. Genunche-Dumitrescu,
I.-G. Diaconu (Bals, Craiova, RO)

29. Inflammatory articular disease in patients with inflammatory bowel disease
C.I. Deliu, O.M. Diaconu, A.-V. Genunche-Dumitrescu, D. Neagoe, N. Deliu
(Bals, Craiova, RO)

30. Osteo-articular manifestations in inflammatory bowel diseases – Diagnosis
and treatment
O.M. Diaconu, I.-G. Diaconu, C.I. Deliu, A.-V. Genunche-Dumitrescu,
D. Neagoe (Craiova, Bals, RO)

31. The incidence of extradigestive manifestations in intestinal inflammatory
diseases
O.M. Diaconu, I.-G. Diaconu, C.I. Deliu, A.-V. Genunche-Dumitrescu,
D. Neagoe (Craiova, Bals, RO)

32. Adverse effects of infliximab therapy in inflammatory bowel diseases
O.M. Diaconu, I.-G. Diaconu, C.I. Deliu, A.-V. Genunche-Dumitrescu,
D. Neagoe (Craiova, Bals, RO)

33. Efficacy and safety of hepatitis C treatment with direct antiviral agents
(DAAs) and ribavirin in patients with ulcerative colitis (UC) with stable
disease under treatment
D. Dimitroulopoulos, I. Elefsiniotis, V. Sevastianos, S. Karatapanis,
G. Sofianidis, X. Tsamakidis, D. Kypreos, K. Tsamakidis (Athens, Rhodos, GR)

34.* Vedolizumab: Effects on liver function in an IBD and IBD/PSC cohort
J. Doherty, S. O’Reilly, D. Keegan, M. Buckley, G. Horgan, H. Mulcahy,
G. Cullen, G. Doherty, J. Sheridan (Dublin, IE)

35. Peach pit as a cause of small bowel obstruction in patient with Crohn’s disease
V. Domislovic, M. Brinar, N. Turk, S. Cukovic-Cavka, A. Barisic, T. Kekez,
Z. Krznaric (Zagreb, HR)

36.* Tuberculosis infection in inflammatory bowel disease patients on anti-TNF
therapy: Experience from an endemic country
N. Elleuch, W. Dahmani, H. Jaziri, A. Ben Slama, A. Hammami, A. Brahem,
S. Ajmi, M. Ksiaa, A. Jmaa (Sousse, TN)

37. Phenotype and clinical outcomes of older-onset Crohn’s disease
H. Elloumi, M. Ben Hmida, A. Belkhamsa, S. Ben Hmida, S. Bouaziz,
I. Cheikh (Bizerte, TN)

38. Gender-related differences in clinical course of Crohn’s disease: A Tunisian
retrospective study
H. Elloumi, M. Ben Hmida, S. Bouaziz, A. Belkhamsa, S. Ben Hmida,
I. Cheikh (Bizerte, TN)

39. The spectrum of pathological changes in patients with Crohn’s disease
under long-term mesalamine treatment
40. Predicting good or bad prognosis in IBD: The role of disorders of the rheological properties of erythrocytes
O.V. Fedorova, G.Y. Levin, A.N. Popovicheva, L.N. Sosnina, Y.A. Sheremet’ev
(Nizhny Novgorod, RU)

41. Morphological criteria for prediction of the causure of ulcerative colitis in children
E. Fedulova (Nizhny Novgorod, RU)

42. Acceptance and commitment therapy improves body image in inflammatory bowel disease patients
A. Fennessy, L. McHugh, C. Rowan, B. Wynne, D. Keegan, K. Byrne,
K. Hartery, B. Dooley, H. Mulcahy (Dublin, IE)

43. Long-term follow-up in children with inflammatory bowel disease at different age of onset
J. Gallo, V. Yusti Caicedo, J. Cohen Sabban, V. Busoni, D. D'Agostino, M. Orsi
(Buenos Aires, AR)

44. Epidemiological profile of perianal Crohn's disease in Tunisian population
H. Gdoura, A. Siala, M. Boudabous, L. Chtourou, A. Amouri, L. Mnif,
N. Tahri (Sfax, TN)

45. The short-term immunosuppressive therapy for induction of remission of the steroid-refractory ulcerative colitis in elderly patients
A.-V. Genunche-Dumitrescu, D. Badea, M. Badea, P. Mitrut, C.I. Deliu,
A. Badea (Craiova, Bals, RO)

46. The study of the mechanism of the development of Crohn’s disease in women with endometriosis
D. Gordienko (Rostov-on-Don, RU)

47. Molecular mechanisms of sensorineural hearing loss as the extraintestinal manifestation of inflammatory bowel diseases
E. Gordienko (St. Petersburg, RU)

48. Study on clinical remission and mucosal healing in subtypes of Crohn’s disease patients by short-term combination therapy
Y. Gu, Q. Wu, J. Zhong (Shanghai, CN)

49. A patient with Crohn’s disease during remission by biological agent treatment, then developed active pulmonary tuberculosis: Determining the eating habits
M. Guney, M. Erdil, G. Basaranoglu, M. Basaranoglu (Istanbul, TR)

50.* Vitamin D status and polymorphisms of its receptor gene during Crohn’s disease: Results of a prospective comparative study
D. Habiba, M. Sergyuni, D. Saadouli, J. Boubaker (Tunis, TN)

51. Fatal cerebro-meningeal haemorrhage complicating a Crohn's disease
L. Hamzaoui, H. Ayadi, M. Medhioub, A. Ben Mohamed, M. Mahmoudi,
A. Khsiba, M.M. Azouz (Nabeul, TN)

52. Choledochoduodenal fistula complicating a Crohn's disease: A case report
L. Hamzaoui, H. Ayadi, M. Medhioub, A. Khsiba, M. Mahmoudi, M.M. Azouz
(Nabeul, TN)
53. Prolonged azathioprine treatment reduces the need for surgery in early Crohn’s disease
   L. Hamzaoui, A. Ben Mohamed, M. Medhioub, M. Mahmoudi, A. Khsiba, M.M. Azouz (Nabeul, TN)

54. Validation of the CUCQ questionnaire with stoma extension in patients with acute ulcerative colitis in the CONSTRUCT trial
   H. Hutchings, L. Alrubaiy, A. Watkins, W.-Y. Cheung, A.C. Seagrove, I.T. Russel, J.G. Williams (Swansea, GB)

55. Hematological status of Crohn’s disease patients who underwent the same type of surgery
   G. Iliescu, M. Cheie, G. Tene, A. Iordache, A. Neagoe (Craiova, RO)

56. T regulatory, T helper 17 and T effector cell profile in patients with ulcerative colitis on anti-TNFα therapy

57. Comparison of histological reports after various types of treatment and after achievement of clinical and endoscopic remission in patients with ulcerative colitis (UC)
   D. Janelidze, N. Omanidze (Kiev, UA; Tbilisi, GE)

58. Efficacy and safety of azathioprine and methotrexate for maintaining remission in microscopic colitis: Outcomes from a district general hospital
   H.E. Johnson, S. McLaughlin (Bournemouth, GB)

59. The imbalance of the homeostasis serine proteases inhibitors in inflammatory bowel disease naive patients: A horizon for new perspectives therapies?
   R. Kallel, L. Chtourou, A. Amouri, A. Jablaoui, A. Gargouri, M. Boudabbous, H. Gdoura, M. Rhimi, L. Mnif, N. Tahri (Sfax, TN; Jouy-en-Josas, FR)

60. The prevalence of extraintestinal manifestations in patients with IBD
   M. Katsaros, A. Katsoula, N. Dimitriadis, K. Tziogkas, S. Karampatsou, A. Tsimperidis, N. Grammatikos, K. Soufleris, O. Giouleme (Thessaloniki, GR)

61. Causes of switching anti-TNFα agents in patients with IBD – A single-center experience
   M. Katsaros, A. Katsoula, N. Dimitriadis, K. Tziogkas, S. Karampatsou, A. Tsimperidis, N. Grammatikos, K. Soufleris, O. Giouleme (Thessaloniki, GR)

   M. Katsaros, A. Katsoula, N. Dimitriadis, K. Tziogkas, S. Karampatsou, A. Tsimperidis, N. Grammatikos, K. Soufleris, O. Giouleme (Thessaloniki, GR)

63. How effective are treatments in prevention of hypercoagulability and thromboembolic events in ulcerative colitis patients?
64. Proactive approach of therapeutic drug monitoring (TDM) in pediatric inflammatory bowel disease (PIBD) on maintenance biologic treatment improves clinical remission
F. Kiparissi, S. Sider, R. Wearon, S. Chadokufa (London, GB)

65. Rheumatological manifestations of Crohn's disease: A monocentric study in Turkish population

66. Biosimilar infliximab in clinical practice of IBD patients
M. Konceny (Olomouc, CZ)

67. Protective effect of mesalazine on thromboembolic event risk in Crohn's disease

68. Incidence of inflammatory bowel disease across Croatia: Is there a difference between north and south?
A. Krizman, Z. Sundov (Split, HR)

69. Audit into the frequency of reactions to intravenous iron infusions
A. Lewis, G. Lloyd-Ford, M.R. Gordon, K. Fortey (Newport, GB)

70. Safety of accelerated infliximab infusion in inflammatory bowel disease in a district general hospital
J. Luk, P. Avery, R. Wilson, A. Lock, E. Webb, J. Jupp, A. Castro-Silva, S. Bridger, J. Shutt (Dorchester, GB)

71. Is there a role for budesonide in maintenance of remission in Crohn's disease?
Z. Mahovne (Slavonski Brod, HR)

72.* Gal-SWITCH: A prospective study of planned switch from infliximab bio-originator Remicade® to bio-siimilar Inflectra®
N. Mc Gettigan, A. Keogh, E. Slattery (Galway, IE)

73. Fecal HSF2 concentration maybe used as an evaluation index for predicting mucosal healing of ulcerative colitis
Y. Miao (Kunming, CN)

74. Infliximab therapy and deviations in platelet indices in Crohn's disease patients – A single-center experience
A. Michalak, H. Cichoź-Lach, B. Kasztelan-Szczerbinska, K. Laskowska, P. Radwan (Lublin, PL)

75. Association between IL12B gene polymorphisms and the risk of Crohn's disease in Serbian patients with inflammatory bowel disease
D. Mijac, S. Dijuranovic, D. Bojic, I. Vukovic Petrovic, D. Popovic, D. Culafic, I. Jovicic, V. Pravica, M. Markovic (Belgrade, RS)

76. Colectomy-free survival and factors associated with it in children with ulcerative colitis managed in a tertiary IBD centre in the UK
R. Muhammed, S.-Y. Ong, W. Haller (Birmingham, GB)
77. Effect of vedolizumab therapy on clinical remission, including remission of peripheral arthropathy, in patient with Crohn’s disease and previous tumor necrosis factor antagonist failure
A. Muslim, M. Nikolic, J. Muslim, M. Zivkovic, N. Blazevic, I. Budimir, Z. Dorosulic, D. Hrabar, A. Biscanin (Sisak, Zagreb, HR)

78.* PROFILE trial: PRedicting Outcomes For Crohn’s Disease using a moLecular biomarker

79. V565, a novel oral anti-TNF domain antibody, binds to mucosal macrophages and T cells, and reduces colonic mucosal inflammation after 6 days oral dosing to ulcerative colitis (UC) patients

80. Evaluation of the thiopurine therapy in children suffering inflammatory bowel disease
A. Ochocinska, A. Czajkowska, Z.T. Wawer, M. Filipek, R.M. Janas (Warsaw, PL)

81. Colectomy place in ulcerative colitis patients who received mesalamine treatment

82. Clinical expression of inflammatory bowel diseases – A retrospective population-based cohort study; Vukovar-Srijem county, Croatia, 2010
D. Pezerovic, M. Zulj, I. Klarin, L. Majnaric, I. Vcev, A. Vcev (Vinkovci, Osijek, Zadar, HR)

83.* Opportunistic infections, mesenteric vessels endothelial dysfunction and colonic resistance in IBD have possible genetic background for challenging clinical situations
O.M. Plehutsa, L.P. Sydorchuk, B. Syrota, I. Sydorchuk, A. Vakarchuk, A.R. Sydorchuk, R.I. Sydorchuk (Chernivtsi, UA)

84.* Expression of PCNA protein in comparison with inflammatory cells infiltration in Crohn’s disease
A. Pryczynicz, J. Zinczuk, W. Ustymowicz, M. Niziol, P. Kuczynska, K. Zareba, K. Guzinska-Ustymowicz (Bialystok, PL)

85. Golimumab in ulcerative colitis: A multicentre real world experience

86. Corticosteroid therapy and ursodeoxycolic acid therapy in patient with primary sclerosing cholangitis and psychosis – Case report
M. Razov Radas (Zadar, HR)

87. Inhibition of Ras by farnesylthiosalicylic acid (FTS) is a potential target of treatment of experimental colitis
S. Reif, T. Oron (Jerusalem, Petah Tikva, IL)
88. An investigation of taste preferences and attitudes towards long-term use of oral nutritional supplement drinks in adolescent and adult Crohn’s disease
N. Richards, N. Davies, K. Keetarut (London, GB)
89. Severe extensive ulcerative colitis: A case of good and fast response to treatment
L. Rivas (Lima, PE)
90. Malnutrition in Tunisian Crohn’s disease cohort
H. Romdhane, B. Bouchabou, N. Bellil, H. Ben Nejma, R. Ennaifer (Tunis, TN)
91. Intra-abdominal abscesses complicating Crohn’s disease: Clinical and therapeutic features
H. Romdhane, B. Bouchabou, H. Ben Nejma, N. Bellil, R. Ennaifer (Tunis, TN)
92. Severe disease activity in ulcerative colitis associated with mucosal hypoxia measured endoscopically
C. Rowan, E. Brown, E. Ryan, C. Taylor, G. Doherty (Dublin, IE)
93. Risk factors for ocular involvement during Crohn's disease
D. Saadouli, S. Yahyaoui, A. Sammoud, M.A. El Efrit (Tunis, TN)
94. Crohn's disease or Behçet’s disease?
D. Saadouli, S. Yahyaoui, A. Sammoud, M.A. El Efrit (Tunis, TN)
95. Insights into mechanisms and new treatment options of ulcerative colitis in patients with latent autoimmune diabetes
I. Sarvilina (Rostov-on-Don, RU)
96. Systematic review of the clinical disease severity indices for inflammatory bowel disease
97. Can the inflammatory bowel disease biologics registry lead to improved quality of care?
S. Shwana, I. Rikaby, L. Alrubaiy, H. Hutchings, J.G. Williams (Merthyr Tydfil, Cardiff, Swansea, GB)
98. The development of a nurse-led inflammatory bowel disease outpatient clinic: Meeting the needs of adolescents with inflammatory bowel disease
S. Sider, S. Chadoufa, R. Buckingham, B. Huggett, F. Kiparis (London, GB)
99. Biosimilar infliximab (CT-P13) is effective in induction of remission and mucosal healing in paediatric Crohn’s disease: A single-centre experience
M. Sladek, M. Chmielowska, A. Wasilewska, I. Herman-Sucharska, S. Pieczarkowska (Krakow, PL)
100. Phenotypic variation in monogenic inflammatory bowel diseases – Glycogen storage disease 1B as an illustration
M. Slae, M. Wilschanski (Jerusalem, IL)
101. Inflammatory bowel disease (IBD) in a patient with immunodeficiency – Is bone marrow transplant indicated?
M. Slae, P. Millman (Jerusalem, IL)
102. Treatment of patients with Crohn's disease and ulcerative colitis with manifestation arthritis and spondylitis
V. Sulyma, O. Sulima (Dnipro, UA)

103. Systematic review: Psychosocial factors associated with pain in inflammatory bowel disease

104. The role of different E. coli variants emphasizing opportunistic infection and colonic resistance in inflammatory bowel disease

105. Analysis of allele’s distribution and the association between the TGF-β1 gene’s polymorphism and IBD
L.P. Sydorchuk, P.D. Fomin, R.I. Sydorchuk, O.M. Plehutsa, I. Sydorchuk, A.R. Sydorchuk, I. Plehutsa (Chernivtsi, Kiev, UA)

106. Personalizing approach to IBD trough pro-, anti-inflammatory cytokines and genetic polymorphisms

107.* Does drug level monitoring help us to understand the superiority of thiopurine and anti-TNF combination therapy in inflammatory bowel diseases?

108.* Dietary patterns in patients with inflammatory bowel disease
I. Tadin Hadjina, P.M. Zivkovic, A. Matetic, J.A. Borovac, J. Bukic, D. Rusic, A. Tonkic, J. Bozic (Split, HR)

109. Isolated appendiceal orifice inflammation associated with distal ulcerative colitis – A case report
M. Tagle, Y. Scavino, E. Luna (Lima, PE)

110. Position for vedolizumab in the treatment of ulcerative colitis, rescue therapy. Our modestly experiences
R. Tamburic, J. Petkovic-Dabic, T. Barac, A. Dobrovoljski, S. Dabic, S. Trbojevic (Banja Luka, BA)

111. TLR 2, 4, 6 as a tool for prediction of the risk of early relapse of ulcerative colitis
G.N. Tarasova, L. Mamedova (Rostov-on-Don, RU)

112. The role of stool genetic testing (SGT) for differential diagnosis of early stage IBD and IBS
T. Toth, D. Krizsan, D. Nyul, E. Bacsur, A. Gelley, P. Demeter, R. Sike, R. Schwab (Budapest, HU)

113. Immunohistochemical expression of proliferation markers in colitis ulcersosa
W. Ustymowicz, J. Zinczuk, M. Baszun, A. Pyczynicz, K. Guzinska-Ustymowicz (Bialystok, PL)
114. The expression of caspase-8 in inflammatory bowel diseases
   W. Ustymowicz, J. Zinczuk, M. Baszun, A. Pryczynicz, K. Guzinska-Ustymowicz, K. Zareba (Bialystok, PL)
115. Virtual biologics clinic for IBD in a district general hospital
   A. Vaishnavi, K. Johns, F. Ali (Pembrokeshire, GB)
116. Primary immunodeficiency and ulcerative colitis: Are there any points of interaction?
   A.S. Volkov, O. Bashtovaya, A.A. Iakovlev (Rostov-on-Don, RU)
117. Acute severe colitis in pregnancy: A case report
   I.K. Williams (Poole, Dorset, GB)
118.* Infliximab or ciclosporin for steroid-resistant acute severe ulcerative colitis?
    Results of a pragmatic randomised trial and economic evaluation
    (CONSTRUCT)
119.* Serum MMP-9 – A novel biomarker for prediction of clinical relapse in patients with quiescent small bowel Crohn’s disease
120. Profound loss of neprilysin accompanied by decreased levels of neuropeptides and increased CRP in ulcerative colitis
   B. Yildirim, Z. Gok Sargin, N. Erin, G. Tazegul, G.O. Elpek (Antalya, TR)
121. Significance of metalloproteinase 9 (MMP-9) expression in ulcerative colitis
   J. Zinczuk, K. Zareba, P. Kuczynska, W. Ustymowicz, M. Baszun, K. Guzinska-Ustymowicz, A. Pryczynicz (Bialystok, PL)
122. Impairment of cognitive and psychomotor performance in patients with inflammatory bowel disease
   P.M. Zivkovic, I. Tadin Hadjina, M. Vilovic, D. Rusic, A. Tonkic, Z. Puljiz, J. Bozic (Split, HR)

* = Posters of Distinction
List of Speakers, Moderators and Scientific Organizers

Prof. Dr. Matthieu Allez
Service de Gastroentérologie
Hôpital Saint-Louis
1 Ave. C. Vellefaux
75010 Paris
France
matthieu.allez@aphp.fr

Dr. Vito Annese
Valiant Clinic
City Walk, 13th Street
P.O. Box 412496
Dubai
United Arab Emirates
vitoannese1@gmail.com

Dr. Alessandro Armuzzi
IBD Unit
Fondazione Policlinico Gemelli
Complesso Integrato Columbus
Università Cattolica
Via Moscati, 31-33
00168 Rome
Italy
alessandro.armuzzi@unicatt.it

Prof. Dr. Raja Atreya
Medizinische Klinik I
Universitätsklinikum Erlangen
Ulmenweg 18
91054 Erlangen
Germany
raja.atreya@uk-erlangen.de

Dr. Filip Baert
Gastro-enterologie
AZ Delta Campus Wilgenstraat
Wilgenstraat 2
8800 Roeselare
Belgium
filip.baert@azdelta.be

Prof. Dr. Laurent Beaugerie
Department of Gastroenterology
Hôpital Saint Antoine
184, Rue du Faubourg St.-Antoine
75571 Paris
France
laurent.beaugerie@sat.aphp.fr

Prof. Dr. Willem A. Bemelman
Department of Surgery
Univ. van Amsterdam, Tytgat Institute for Liver & Intestinal Research
Meibergdreef 9
1105 AZ Amsterdam
The Netherlands
w.a.bemelman@amc.uva.nl

Dr. Stefanos Bonovas
Department of Gastroenterology
Istituto Clinico Humanitas
Humanitas University
Via Manzoni 56
20089 Rozzano
Italy
sbonovas@gmail.com

Prof. Dr. Franck Carbonnel
Service d’Hépatogastroentérologie
CHU de Bicêtre
Université Paris Sud
78 rue du Général Leclerc
94275 Le Kremlin-Bicêtre
France
franck.carbonnel@bct.aphp.fr

Dr. Yehuda Chowers
Department of Gastroenterology
Rambam Medical Center
P.O. Box 9602
31096 Haifa
Israel
y_chowers@rambam.health.gov.il
Bruce E. Sands, M.D.
Professor of Medicine
Department of Gastroenterology
Mount Sinai School of Medicine
One Gustave L. Levy Place
New York, NY 10029
USA
bruce.sands@mssm.edu

Scott Steele, M.D.
Colorectal Surgery
Cleveland Clinic Main Campus
Mail Code A30
9500 Euclid Avenue
Cleveland, OH 44195
USA
steeles3@ccf.org

Prof. Dr. Stefan Schreiber
Klinik für Innere Medizin I
Universitätsklinikum
Schleswig-Holstein, Campus Kiel
Arnold-Heller-Str. 3 (Haus 6)
24105 Kiel
Germany
s.schreiber@mucosa.de

Prof. Dr. Britta Siegmund
Med. Klinik für Gastroenterologie, Infektionologie und Rheumatologie
Campus Benjamin Franklin (CBF)
Charité Universitätsmedizin
Hindenburgdamm 30
12203 Berlin
Germany
britta.siegmund@charite.de

Prof. Dr. Antonino Spinelli
Unità Operativa di Chirurgia Generale III
Istituto Clinico Humanitas IRCCS
Via Manzoni 56
20089 Rozzano
Italy
antonino.spinelli@humanitas.it

Prof. Dr. Andreas Sturm
Innere Medizin/Gastroenterologie
DRK-Kliniken Westend
Spandauer Damm 130
14050 Berlin
Germany
a.sturm@drk-kliniken-berlin.de

Dr. Simon P.L. Travis
Department of Gastroenterology
Oxford University Hospitals
Oxford OX3 9DU
Great Britain
simon.travis@ndm.ox.ac.uk

Prof. Dr. Maurizio Vecchi
University of Milan - IRCCS
Ca' Granda Ospedale Maggiore Policlinico Foundation
Gastroenterology Unit
Via Francesco Sforza 35
20122 Milano
Italy
maurizio.vecchi@unimi.it
Congress Office

During Symposium 213

Congress Office Telephone: +49-175-7795-327

Opening Hours:
Thursday, October 4, 2018 16.00 – 21.00 h
Friday, October 5, 2018 8.00 – 18.00 h
Saturday, October 6, 2018 8.30 – 16.00 h

Milan Marriott Hotel
Via Washington 66
20146 Milan
Italy

Admission to Scientific Program

For admission to scientific events your name badge should be clearly visible.

Conflicts of Interest
Members of the scientific committee declare the following potential conflicts of interest:
Alessandro Armuzzi: MSD, AbbVie, Allergan, Biogen, Celgene, Celltrion, Ferring, Hospira, Janssen, Lilly, Mundipharma, Pfizer, Samsung Bioepis, Sofar, Takeda, AstraZeneca, Chiesi, Medtronic, Mitsubishi Tanabe, Nikkiso, Otsuka, Tigenix, Zambon; Silvio Danese: AbbVie, Ferring, Hospira, Johnson and Johnson, Merck, MSD, Takeda, Mundipharma, Pfizer, Tigenix, UCB Pharma, Vifor, Biogen, Celgene, Allergan, Celltrion, Sandoz, Boehringer Ingelheim; Axel Dignass: AbbVie, MSD, Ferring, Roche, Takeda, Pharmacosmos, Vifor, Falk Pharma, Mundipharma, Janssen, Hospira, Robarts, Pfizer, Sandoz, Celgene, Tillotts, Falk Foundation, Otsuka, Immundiagnostik, Med Update GmbH, Medice, Wiley, Thieme, Allergosan, Pharmacosmos; Paolo Gionchetti: Janssen, Abbvie, Pfizer, Celgene, Takeda, Ferring, MSD, Alfa Wasserman, Amgen, Sofar, Chiesi
Airport

Milano Malpensa Airport
Distance to hotel: 49 km; Taxi fare approx.: EUR 90
http://www.milanomalpensa-airport.com/en

Linate Airport
Distance to hotel: 12 km; Taxi fare approx.: EUR 35
http://www.milanolinate-airport.com/en

Orio al Serio International Airport
Distance to hotel: 55 km; Taxi fare approx.: EUR 100
http://www.milanbergamoairport.it/en/

Parking
The hotel offers parking spaces on first come first serve basis.
(2,10€ hourly, 15€ daily)
International Symposia and Workshops

Scientific Dialogue in the Interest of Therapeutic Progress

Workshop
From Viral Hepatitis to Chronic Inflammation and Liver Cancer
Heidelberg, Germany
February 21–22, 2019

Symposium 214
IBD: From Pathophysiology to Personalized Medicine
Oxford, Great Britain
March 29–30, 2019

Symposium 215
IBD: From Diagnosis to Therapy
St. Petersburg, Russia
July 5–6, 2019

Symposium 216
Building Bridges in IBD
Brussels, Belgium
September 13–14, 2019

Symposium 217
West Meets East: Functional Meets Organic Gastrointestinal Diseases
Singapore
November 29–30, 2019

FALK FOUNDATION e.V.
Leinenweberstr. 6
79108 Freiburg
Germany

Congress Department
Tel.: +49 (0)761/1514-125
Fax: +49 (0)761/1514-359
E-Mail: symposia@falk-foundation-symposia.org
www.falk-foundation-symposia.org

2019